Krystal Biotech (KRYS) Stock Price, News & Analysis

Company Overview

Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen. The therapy delivers a functional copy of the COL7 gene and received approval from the U.S. Food and Drug Administration in 2023. Krystal also has investigational programs targeting other rare conditions, including genetic diseases affecting the lungs and skin.

Founded in 2015 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech initially focused on advancing its gene-delivery platform through clinical development before expanding into commercial operations. The company’s primary commercial focus has been the United States, while it continues to pursue regulatory and development opportunities in international markets. Krish S. Krishnan, a co-founder, serves as the company’s chief executive officer.

Key Stats

• Today's Range: $297.52 to $305.60
• 50-Day Range: $295.90 to $371.47
• 52-Week Range: $192.52 to $382.54
• Volume: 234,200 shs
• Average Volume: 308,209 shs
• Market Capitalization: $8.91 billion
• P/E Ratio: 40.83
• Dividend Yield: N/A
• Price Target: $375.00
• Consensus Rating: Moderate Buy

Krystal Biotech Stock Analysis - MarketRank™

Krystal Biotech scored higher than 83% of companies evaluated by MarketBeat, and ranked 61st out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Krystal Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 2 strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Krystal Biotech has a consensus price target of $375.00, representing about 24.6% upside from its current price of $300.88.

Amount of Analyst Coverage

Krystal Biotech has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 15.12%

Earnings Growth

Earnings for Krystal Biotech are expected to grow by 15.12% in the coming year, from $7.74 to $8.91 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Krystal Biotech is 40.83, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.50.

Price to Earnings Ratio vs. Sector

The P/E ratio of Krystal Biotech is 40.83, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.54.

Price to Book Value per Share Ratio

Krystal Biotech has a P/B Ratio of 6.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.41% of the float of Krystal Biotech has been sold short.

Short Interest Ratio / Days to Cover

Krystal Biotech has a short interest ratio ("days to cover") of 10.33, which indicates bearish sentiment.

Change versus previous month

Short interest in Krystal Biotech has recently decreased by 15.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Krystal Biotech does not currently pay a dividend.

Dividend Growth

Krystal Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.46

News Sentiment

Krystal Biotech has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 37 news articles for Krystal Biotech this week, compared to 5 articles on an average week.

Search Interest

Only 4 people have searched for KRYS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

7 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,211,000.00 in company stock.

Percentage Held by Insiders

13.10% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/02/2026
• Today: 11/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KRYS
• CIK: 1711279
• Web: www.krystalbio.com
• Phone: (412) 586-5830
• Fax: N/A
• Employees: 295
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Krystal Biotech: $375.00
• High Price Target: $474.00
• Low Price Target: $284.00
• Potential Upside/Downside: +24.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.93
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $7.37
• Trailing P/E Ratio: 40.83
• Forward P/E Ratio: 33.77
• P/E Growth: N/A
• Net Income: $204.83 million
• Net Margins: 47.91%
• Pretax Margin: 55.06%
• Return on Equity: 17.02%
• Return on Assets: 15.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.32
• Quick Ratio: 7.96

Sales & Book Value

• Annual Sales: $389.13 million
• Price / Sales: 22.89
• Cash Flow: $7.41 per share
• Price / Cash Flow: 40.59
• Book Value: $48.50 per share
• Price / Book: 6.20

Miscellaneous

• Outstanding Shares: 29,600,000
• Free Float: 25,751,000
• Market Cap: $8.91 billion
• Optionable: Optionable
• Beta: 0.56